BioInvent International AB 2026 Sustainability Report
The report presents BioInvent's sustainability declaration for its fully integrated cancer-immunotherapy organization, covering governance, value-chain, workforce and environmental topics. It describes a double materiality assessment and prioritizes SDGs 3, 9, 10 and 17. The declaration reports 2024 gross GHG emissions of 491,958 tCO2e, including Scope 1 of 0, Scope 2 of 16.47 and Scope 3 of 475.489 tCO2e, alongside total energy use of approximately 1,339 MWh and waste of 15 tonnes. It also reports 126 employees at year-end and 40% women on the board, and states that ISO 26000 verification was achieved.
Company: BioInvent International AB
Sector: Professional & technical services
Country: Sweden
Year: 2026
Type: Sustainability Report
Pages: 71
Back to company
BioInvent International AB
Sustainability Declaration
The report presents BioInvent's sustainability declaration for its fully integrated cancer-immunotherapy organization, covering governance, value-chain, workforce and environmental topics. It describes a double materiality assessment and prioritizes SDGs 3, 9, 10 and 17. The declaration reports 2024 gross GHG emissions of 491,958 tCO2e, including Scope 1 of 0, Scope 2 of 16.47 and Scope 3 of 475.489 tCO2e, alongside total energy use of approximately 1,339 MWh and waste of 15 tonnes. It also reports 126 employees at year-end and 40% women on the board, and states that ISO 26000 verification was achieved.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2026
Reporting Period
2025
Fiscal Year
2025
Published
Jan 23, 2026
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees